Predicting survival in hepatitis B

Sherman, M.
November 2005
Gut;Nov2005, Vol. 54 Issue 11, p1521
Academic Journal
The article focuses on the treatment of chronic hepatitis B infection. Predictors of survival in chronic hepatitis B infection are surprisingly not well described. Various studies have identified different factors that were associated with adverse outcomes. Alanine aminotransferase (ALT) level alone is not an appropriate indication for therapy in chronic hepatitis B infection, and other criteria in addition to ALT must be used to determine eligibility for therapy. Given the uncertainty about appropriate treatment end points, it is perhaps not surprising that the indications chosen for starting therapy have been unsatisfactory.


Related Articles

  • FROM INACTIVE CARRIER TO REACTIVATION OF HEPATITIS B VIRUS. Nicoliţă, Diana; Sporea, Ioan; Şirli, Roxana; Dan, Isabel; Vernic, Corina // Fiziologia - Physiology;2010, Vol. 20 Issue 1, p42 

    Background and aim: The natural evolution of the hepatitis B virus infection depends on the host immune system status. The aim of this paper is to evaluate time dynamics of the HBV-DNA viral load in HBsAg carriers in order to see how many of them remain in an inactive state and how many progress...

  • Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. Hadziyannis, Stephanos J.; Tassopoulos, Nicolaos C.; Heathcote, E. Jenny; Chang, Ting-Tsung; Kitis, George; Rizzetto, Mario; Marcellin, Patrick; Lim, Seng Gee; Goodman, Zachary; Ma, Jia; Arterburn, Sarah; Xiong, Shelly; Currie, Graeme; Brosgart, Carol L. // New England Journal of Medicine;6/30/2005, Vol. 352 Issue 26, p2673 

    Background: Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B. We evaluated the effect of continued therapy as compared with cessation of therapy....

  • The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease. LIANG, J.; HAN, T.; GAO, Y.-T.; JING, L.; MA, Z. // European Review for Medical & Pharmacological Sciences;Nov2015, Vol. 19 Issue 21, p4123 

    OBJECTIVE: Chronic hepatitis B patients with fatty liver disease are gradually increasing. We aim to investigate the serum fragment level of cytokeratin 18 (CK-18), M30 and M65, in chronic hepatitis B (CHB) patients with and non-alcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: Serum...

  • Interferon-Alpha-2a and Zinc Combination Therapy in Children with Chronic Hepatitis B Infection. Kuloğlu, Zarife; Kırbaş, Gülnihan; Erden, Esra; Kansu, Aydan // Biological Trace Element Research;Dec2011, Vol. 143 Issue 3, p1302 

    Zinc has been reported to enhance the response to interferon (IFN) or PEG-IFN plus ribavirin therapy, improve liver function, and ameliorate hematologic side effects in patients with chronic hepatitis C. However, the role of zinc supplementation during IFN therapy in chronic hepatitis B...

  • Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B. Suk Jin Hong; Yeo Hyang Kim; Byung-Ho Choe; Hyo Jung Park; Won-Young Tak; Young-Oh Kweon // Pediatric Gastroenterology, Hepatology & Nutrition;Jun2013, Vol. 16 Issue 2, p80 

    Purpose: To identify the predictive factors of long-term therapeutic response or resistance to lamivudine treatment in children and adolescents with chronic hepatitis B. Methods: Eighty one children and adolescents with chronic hepatitis B were included, who received lamivudine treatment for at...

  • Therapeutic options for chronic hepatitis B in 2013. Asselah, Tarik; Marcellin, Patrick // Hot Topics in Viral Hepatitis;2013, Vol. 9 Issue 28, p8 

    In recent years, many improvements have been made in prevention and treatment of hepatitis B virus (HBV) infection--one of the major causes of chronic hepatic diseases: cirrhosis and hepatocellular carcinoma (HCC). The aim of this therapy is preventing the progression of the disease through...

  • Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. H. WANG; Y. Y. JI; G. B. YAO; X. Y. MA; Q. XIE; H. Y. PANG; S. M. WU; J. LI; C. W. CHEN; X. W. XU; E. L. GU // European Review for Medical & Pharmacological Sciences;Mar2013, Vol. 17 Issue 5, p636 

    BACKGROUND: Lamivudine (LAM) and adefovir (ADV) are widely used in most Asian countries, though monotherapy is associated with the occurrence of resistance. AIM: To evaluate the efficiency of LAM and ADV combined treatment of chronic hepatitis B patients with compensated cirrhosis. PATIENTS AND...

  • The curative effect of adefovir dipivoxil treating HbeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Junsheng Gu; Ranran Sun; Shen Shen; Zujiang Yu // Pakistan Journal of Pharmaceutical Sciences;Jul2015 Supplement, Vol. 28, p1493 

    This study aimed to research the efficiency of adefovir dipivoxil in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treatment and in combination with D-2b interferon in the treatment of HBeAg-positive chronic hepatitis B. A total of 102 cases of adult patients with HBeAg chronic...

  • Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B. Sarin, Shiv Kumar; Sood, Ajit; Kumar, Manoj; Arora, Anil; Amrapurkar, Deepak; Sharma, Barjesh Chander; Konar, Ashokananda; Chawla, Yogesh Kumar; Jain, Rajendra Kumar; Nanda, Vijay; Kumar, Arun; Hissar, Syed; Lavate, Piramal; Lahoti, Deepak // American Journal of Gastroenterology;Jan2007, Vol. 102 Issue 1, p96 

    BACKGROUND: Lower hepatitis B virus DNA (HBV DNA) levels are associated with better responses in chronic hepatitis B (CHB). It is unclear whether an initial phase of antiviral treatment to lower HBV DNA levels before adding immunomodulator therapy is more effective than the strategy of using...


Read the Article


Sign out of this library

Other Topics